Premium
CA19‐9 as a predictor of recurrence in patients with colorectal cancer
Author(s) -
Nakayama Takamori,
Watanabe Masahiko,
Teramoto Tatsuo,
Kitajima Masaki
Publication year - 1997
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/(sici)1096-9098(199712)66:4<238::aid-jso3>3.0.co;2-c
Subject(s) - medicine , ca19 9 , colorectal cancer , immunostaining , adjuvant therapy , cancer , tumor m2 pk , gastroenterology , tumor progression , oncology , tumor marker , immunohistochemistry , pancreatic cancer
Background and Objectives CA19‐9 is a cancer‐associated carbohydrate antigen that plays a role in the process of tumor progression as an adhesion molecule. Methods We evaluated the prognostic value of CA19‐9 tumor expression and CA19‐9 preoperative and postoperative serum levels in colorectal cancer patients treated by complete resection. The most powerful discrimination was achieved using the three CA19‐9 markers in combination. Results CA19‐9 tumor expression was identified by immunostaining in 71.0% (86/121) of primary carcinomas. Positive CA19‐9 serum levels (≥37 U/ml) were restricted to cases with positive tumor expression, and CA19‐9 was detected more frequently in preoperative serum (20.6%, 25/121) than in 1‐month postoperative serum (6.6%, 8/121). Positive tumor expression, positive preoperative serum level, and positive postoperative serum level were all predictive of increased cancer mortality. Patients with three negative parameters had no recurrences and 97.1% 5‐year survival, whereas patients with three positive parameters had 62.5% recurrence and 42.8% 5‐year survival. Conclusions CA19‐9 detection in tumor tissue and serum identified patients at high risk of cancer recurrence and death and may be useful in selecting patients for adjuvant therapy. J. Surg. Oncol. 1997;66:238–243. © 1997 Wiley‐Liss, Inc.